Method of treating atopic dermatitis or asthma using antibody to IL4RA
First Claim
Patent Images
1. A method of treating or reducing the risk of atopic dermatitis or asthma in a human in need thereof, the method comprising administering to said human an antibody or antibody fragment that specifically binds a human IL4Ra protein that comprises a mutation selected from the group consisting of I75V, E400A, C431R, S503P, Q576R and S752A in SEQ ID NO:
- 67;
wherein (i) the antibody or fragment comprises a VH domain derived from the recombination of a human VH segment, a human D gene segment and a human JH segment, the human VH segment encoding the framework 1 of SEQ ID NO;
40 and wherein said human comprises a VH gene segment encoding the framework 1 of SEQ ID NO;
40, or the human expresses VH domains that comprise the framework 1 of SEQ ID NO;
40; and
wherein (ii) said human comprises a nucleotide sequence encoding said IL4Ra protein comprising said selected mutation.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
190 Citations
21 Claims
-
1. A method of treating or reducing the risk of atopic dermatitis or asthma in a human in need thereof, the method comprising administering to said human an antibody or antibody fragment that specifically binds a human IL4Ra protein that comprises a mutation selected from the group consisting of I75V, E400A, C431R, S503P, Q576R and S752A in SEQ ID NO:
- 67;
wherein (i) the antibody or fragment comprises a VH domain derived from the recombination of a human VH segment, a human D gene segment and a human JH segment, the human VH segment encoding the framework 1 of SEQ ID NO;
40 and wherein said human comprises a VH gene segment encoding the framework 1 of SEQ ID NO;
40, or the human expresses VH domains that comprise the framework 1 of SEQ ID NO;
40; andwherein (ii) said human comprises a nucleotide sequence encoding said IL4Ra protein comprising said selected mutation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
- 67;
Specification